

Michigan Pharmacy and Therapeutics Committee
CNS Drugs Workgroup
October 2007

Following review and discussion, the workgroup recommends the following to the full Committee for its consideration at the December meeting:

Alzheimer's Dementia

- No change to the current classification of drugs in this class
- Exelon patches should be added to the PDL without prior authorization

Anti-Anxiety-General

- Remove doxepin from this list
- No other changes to the classification of drugs in this category

Drugs for ADHD

- Maintain the clinical edit on drugs in this category
- No change to the current classification of drugs in the class
- Vyvanse as a new drug to be added to the PDL with prior authorization

Sedative Hypnotic Non Barbiturates

- Remove chloral hydrate, chloral hydrate syrup, diphenhydramine, flurazepam from the class listing on the PDL
- No other changes to the current classification of drugs in the class

The workgroup reviewed the current clinical edit wherein use of one or more of these products for more than three months in the same beneficiary requires prior authorization for continued use. The basic review in these circumstances asks the requesting prescribing physician for the nature of the chronic sleep disorder, counseling on sleep hygiene measures and non drug treatments for the insomnia, list of all known prescribers, medications and diagnoses associated with the insomnia, why Medicare Part D covered medications are not suitable in a Medicare eligible beneficiary, and the specialty of the prescriber. If the request is from a psychiatrist or a neurologist and the co-occurring diagnosis involves other mental health disorders, then the request is authorized. Other requests are reviewed by physicians on a case by case basis.

This protocol was discussed and again approved by the workgroup.